Amgen (AMG) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AMG Analyst Ratings

Moderate Buy

9 Buy

16 Hold

2 Sell

Based on 27 analysts giving stock ratings to

Amgen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AMG Stock 12 Month Forecast

Average Price Target

CHF334.08

▼(-5.43% Downside)

Based on 27 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is CHF334.08 with a high forecast of CHF416.15 and a low forecast of CHF191.43. The average price target represents a -5.43% change from the last price of CHF353.27.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"190":"CHF190","417":"CHF417","246.75":"CHF246.8","303.5":"CHF303.5","360.25":"CHF360.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":416.14856,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF416.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":334.0768266017391,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF334.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":191.4283376,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF191.43</span>\n  </div></div>","useHTML":true}}],"tickPositions":[190,246.75,303.5,360.25,417],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,355.181,359.8708123076923,364.5606246153846,369.2504369230769,373.9402492307692,378.6300615384615,383.3198738461538,388.00968615384613,392.69949846153844,397.38931076923075,402.07912307692305,406.76893538461536,411.45874769230767,{"y":416.14856,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,355.181,353.5576020462876,351.9342040925752,350.31080613886286,348.6874081851505,347.0640102314381,345.44061227772573,343.8172143240134,342.193816370301,340.5704184165886,338.94702046287625,337.3236225091639,335.7002245554515,{"y":334.0768266017391,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,355.181,342.5846413538461,329.9882827076923,317.3919240615385,304.7955654153846,292.1992067692307,279.6028481230769,267.0064894769231,254.41013083076922,241.81377218461537,229.21741353846153,216.62105489230768,204.02469624615384,{"y":191.4283376,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":219.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":219.3,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":219.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":221.18,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":221.18,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":221.18,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.093,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.093,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.093,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":225.063,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":288.252,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":320.846,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":355.181,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF416.15

Average Price TargetCHF334.08

Lowest Price TargetCHF191.43

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Louise Chen

Scotiabank

CHF374.53→CHF416.15

Buy

17.80%

Upside

Reiterated

09/29/26

Amgen price target raised to $500 from $450 at ScotiabankAmgen price target raised to $500 from $450 at Scotiabank

Christopher Raymond

Raymond James

―

Hold

―

Reiterated

09/24/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN) and Imunon (NASDAQ: IMNN)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

CHF305.45→CHF341.24

Hold

-3.40%

Downside

Reiterated

09/23/26

Jefferies Sticks to Their Hold Rating for Amgen (AMGN)

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

―

Hold

―

Reiterated

09/23/26

Leerink Partners Remains a Hold on Amgen (AMGN)

David Amsellem

Piper Sandler

CHF380.36

Buy

7.67%

Upside

Reiterated

09/23/26

Piper Sandler Keeps Their Buy Rating on Amgen (AMGN)

Geoff Meacham

Citi

CHF337.08

Hold

-4.58%

Downside

Reiterated

09/23/26

Competitive profile of Amgen's dazodalibep still 'open question,' says CitiCompetitive profile of Amgen's dazodalibep still 'open question,' says Citi

Gregory Renza

Truist Financial

―

Hold

―

Reiterated

09/23/26

Analysts Conflicted on These Healthcare Names: Edgewise Therapeutics (NASDAQ: EWTX), Vertex Pharmaceuticals (NASDAQ: VRTX) and Amgen (NASDAQ: AMGN)

Gary Nachman

Canaccord Genuity

CHF319.6

Hold

-9.53%

Downside

Reiterated

09/23/26

Analysts Offer Insights on Healthcare Companies: Celldex (NASDAQ: CLDX), Adicet Bio (NASDAQ: ACET) and Amgen (NASDAQ: AMGN)

Yaron Werber

TD Cowen

CHF376.2

Buy

6.49%

Upside

Reiterated

09/22/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Mohit Bansal

Wells Fargo

CHF362.05

Hold

2.49%

Upside

Assigned

09/22/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Invivyd (NASDAQ: IVVD) and Humacyte (NASDAQ: HUMA)

Terence Flynn

Morgan Stanley

CHF301.29

Hold

-14.71%

Downside

Reiterated

09/22/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (NASDAQ: AMGN), Ligand Pharma (NASDAQ: LGND) and Compass Therapeutics (NASDAQ: CMPX)

Salveen Richter

Goldman Sachs

CHF374.53

Buy

6.02%

Upside

Reiterated

09/22/26

Amgen: Strengthening Pipeline and Long-Term Growth Upside Support Buy Rating and Unchanged $450 Price Target

Tazeen Ahmad

Bank of America Securities

CHF263.84

Sell

-25.32%

Downside

Reiterated

09/22/26

Amgen Underperform Maintained as Dazodalibep Data Uncertainty Limits Upside; $317 Price Target Unchanged

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/22/26

Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (NASDAQ: ELDN), Viking Therapeutics (NASDAQ: VKTX) and Amgen (NASDAQ: AMGN)

Emily Field

Barclays

CHF316.27

Hold

-10.47%

Downside

Reiterated

09/17/26

Barclays Sticks to Its Hold Rating for Amgen (AMGN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Louise Chen

Scotiabank

CHF374.53→CHF416.15

Buy

17.80%

Upside

Reiterated

09/29/26

Amgen price target raised to $500 from $450 at ScotiabankAmgen price target raised to $500 from $450 at Scotiabank

Christopher Raymond

Raymond James

―

Hold

―

Reiterated

09/24/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN) and Imunon (NASDAQ: IMNN)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

CHF305.45→CHF341.24

Hold

-3.40%

Downside

Reiterated

09/23/26

Jefferies Sticks to Their Hold Rating for Amgen (AMGN)

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

―

Hold

―

Reiterated

09/23/26

Leerink Partners Remains a Hold on Amgen (AMGN)

David Amsellem

Piper Sandler

CHF380.36

Buy

7.67%

Upside

Reiterated

09/23/26

Piper Sandler Keeps Their Buy Rating on Amgen (AMGN)

Geoff Meacham

Citi

CHF337.08

Hold

-4.58%

Downside

Reiterated

09/23/26

Competitive profile of Amgen's dazodalibep still 'open question,' says CitiCompetitive profile of Amgen's dazodalibep still 'open question,' says Citi

Gregory Renza

Truist Financial

―

Hold

―

Reiterated

09/23/26

Analysts Conflicted on These Healthcare Names: Edgewise Therapeutics (NASDAQ: EWTX), Vertex Pharmaceuticals (NASDAQ: VRTX) and Amgen (NASDAQ: AMGN)

Gary Nachman

Canaccord Genuity

CHF319.6

Hold

-9.53%

Downside

Reiterated

09/23/26

Analysts Offer Insights on Healthcare Companies: Celldex (NASDAQ: CLDX), Adicet Bio (NASDAQ: ACET) and Amgen (NASDAQ: AMGN)

Yaron Werber

TD Cowen

CHF376.2

Buy

6.49%

Upside

Reiterated

09/22/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Mohit Bansal

Wells Fargo

CHF362.05

Hold

2.49%

Upside

Assigned

09/22/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), Invivyd (NASDAQ: IVVD) and Humacyte (NASDAQ: HUMA)

Terence Flynn

Morgan Stanley

CHF301.29

Hold

-14.71%

Downside

Reiterated

09/22/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (NASDAQ: AMGN), Ligand Pharma (NASDAQ: LGND) and Compass Therapeutics (NASDAQ: CMPX)

Salveen Richter

Goldman Sachs

CHF374.53

Buy

6.02%

Upside

Reiterated

09/22/26

Amgen: Strengthening Pipeline and Long-Term Growth Upside Support Buy Rating and Unchanged $450 Price Target

Tazeen Ahmad

Bank of America Securities

CHF263.84

Sell

-25.32%

Downside

Reiterated

09/22/26

Amgen Underperform Maintained as Dazodalibep Data Uncertainty Limits Upside; $317 Price Target Unchanged

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/22/26

Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (NASDAQ: ELDN), Viking Therapeutics (NASDAQ: VKTX) and Amgen (NASDAQ: AMGN)

Emily Field

Barclays

CHF316.27

Hold

-10.47%

Downside

Reiterated

09/17/26

Barclays Sticks to Its Hold Rating for Amgen (AMGN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ESTAEstablishment Labs Holdings

LGNDLigand Pharma

HROWHarrow Health

STOKStoke Therapeutics

AXGNAxoGen

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

3 Months

David AmsellemPiper Sandler

Success Rate

15/20 ratings generated profit

Average Return

+5.73%

Copying David Amsellem's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +5.73% per trade.

1 Year

David AmsellemPiper Sandler

Success Rate

20/20 ratings generated profit

Average Return

+24.59%

Copying David Amsellem's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +24.59% per trade.

2 Years

David AmsellemPiper Sandler

Success Rate

20/20 ratings generated profit

Average Return

+34.20%

Copying David Amsellem's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +34.20% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMG Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AMG has received 34 Buy Ratings, 39 Hold Ratings, and 5 Sell Ratings. AMG average Analyst price target in the past 3 months is 334.08.

Each month's total comprises the sum of three months' worth of ratings.

AMG Financial Forecast

AMG Earnings Forecast

Next quarter’s earnings estimate for AMG is CHF4.80 with a range of CHF4.55 to CHF5.11. The previous quarter’s EPS was CHF5.22. AMG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AMG has Performed in-line its overall industry.

AMG Sales Forecast

Next quarter’s sales forecast for AMG is CHF8.33B with a range of CHF8.17B to CHF8.52B. The previous quarter’s sales results were CHF8.35B. AMG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AMG has Performed in-line its overall industry.

AMG Stock Forecast FAQ

What is CH:AMG’s average 12-month price target, according to analysts?

Based on analyst ratings, Amgen’s 12-month average price target is 334.08.

What is CH:AMG’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for CH:AMG, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Amgen a Buy, Sell or Hold?

Amgen has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 16 hold ratings and 2 sell ratings.

What is Amgen’s share price target?

The average share price target for Amgen is 334.08. This is based on 27 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF416.15 ,and the lowest forecast is CHF191.43. The average share price target represents -5.43% Decrease from the current price of CHF353.27.

What do analysts say about Amgen?

Amgen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 27 Wall Streets Analysts.

How can I buy shares of Amgen?

To buy shares of CH:AMG, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Amgen (AMG) Stock Forecast & Price Target

AMG Analyst Ratings

AMG Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amgen

AMG Analyst Recommendation Trends

AMG Financial Forecast

AMG Earnings Forecast

AMG Sales Forecast

AMG Stock Forecast FAQ

Detailed List of Analyst Forecasts